louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02510716: Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention
Official title: Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention: Testing the Feasibility of the Textto4gotobacco Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Cessation
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Mayo Clinic
name: Alliance for Clinical Trials in Oncology
name: Duke Cancer Institute
First posted: 2015-07-29
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the feasibility, acceptability and preliminary efficacy of a Scheduled Gradual Reduction (SGR) intervention via SMS (short message service) text messaging plus SMS Support Messages in decreasing smoking in an older adult rural population. The SGR group (n=20) will receive a four-week SGR program delivered via SMS text messages plus SMS support messages. The control group (n=20) will receive SMS support messages to aid in quitting.


Eligibility criteria: Inclusion Criteria:

1. Over 60 years of age,
2. Have smoked 100 cigarettes in their lifetime and currently smoke five or more cigarettes a day on average,
3. Have an address in a rural census tract defined by a RUCA code of 4-10,
4. Interested in participating in a cessation program,
5. Own a phone that has texting ability and free texting,
6. Have general knowledge of text messaging and
7. Are willing to receive and respond to text messages from the study teams, throughout the duration of the study.

Exclusion Criteria:

1. criteria include non-English speaking patients
2. already participating in a smoking cessation intervention study.

Primary outcomes:
measure: Tobacco cessation, defined as quit rate at 30 days, as measured by self-reported abstinence from tobacco use
timeFrame: 30-days
Secondary outcomes:
measure: Feasibility, as measured by proportion of return text messages
timeFrame: 30 days
measure: Acceptability, as measured by percentage of participants who reported that they would recommend the program to a friend
timeFrame: 30 days
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
References:
citation: Noonan D, Silva S, Njuru J, Bishop T, Fish LJ, Simmons LA, Choi SH, Pollak KI. Feasibility of a text-based smoking cessation intervention in rural older adults. Health Educ Res. 2018 Feb 1;33(1):81-88. doi: 10.1093/her/cyx080.
Clinical trial NCT02869516: Institut Paoli Calmettes Acute Leukemia Database
Official title: Institut Paoli Calmettes Acute Leukemia Database
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Leukemia Diagnosis
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2016-08-17
Enrollment: 27000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with a diagnosis of acute leukemia

Brief summary: Database of Institut Paoli-Calmettes patients diagnosed with Acute Leukemia


Eligibility criteria: Inclusion Criteria:

* Patient with a diagnosis of acute leukemia

Exclusion Criteria:

* Non applicable

Primary outcomes:
measure: Survival of patients with acute leukemia
timeFrame: 10 years
Secondary outcomes:
measure: Collection of patients characteristics
timeFrame: 10 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli-Calmettes
state: Bouches-du Rhône
Study officials:
References:
Clinical trial NCT01225016: Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound
Official title: Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Thyroid Nodules
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2010-10-20
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study will evaluate thyroid nodules using specialized ultrasound imaging methods.


Eligibility criteria: Inclusion Criteria:

* 1. Patients diagnosed with a thyroid nodule 2. Age greater than or equal to 19 years of age 3. Patients must sign informed consent

Exclusion Criteria:

* 1. Women who are pregnant or nursing 2. Patients with pulmonary hypertension, unstable cardiopulmonary condition,or right to left shunt 3. Hypersensitivity to perfluten 4. Psychological condition that renders the patient unable to understand the informed consent

Primary outcomes:
measure: To estimate the accuracy (sensitivity and specificity) of the contrast enhanced ultrasound for characterization of thyroid nodules.
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Universith of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Glenn E Peters, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01808716: Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage
Official title: Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage: Randomized Double-blind Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: low-level laser therapy
muscle damage
Lead sponsor: Universidade Federal de Sao Carlos
Sponsor class: OTHER
Collaborators: name: Universidade Federal do Rio Grande do Norte
First posted: 2013-03-11
Enrollment: 22
Sex: MALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study hypothesis is a decreased muscle damage induced by exercises when low-level laser therapy is applied on body muscles before exercises.

Detailed description: The study assessed males submitted to exercise to induce muscle damage. Creatine kinase levels in blood was quantified in order to identify the magnitude of muscle damage.

Eligibility criteria: Inclusion Criteria:

* healthy males,
* physically active,
* aged between 25-40 years.

Exclusion Criteria:

* smoker, or
* under medicine as anti-inflammatory and/or any drug that could affect normal and physiological conditions and lesion in upper limbs.

Primary outcomes:
measure: Creatine Kinase analysis in blood
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Natal
country: Brazil
facility: Federal Univesity of Rio Grande do Norte
state: Rio Grande do Norte
Study officials:
affiliation: Universidade Federal do Rio Grande do Norte
name: Wouber Hérickson de Brito Vieira, PhD
role: STUDY_DIRECTOR
References:
citation: Vieira WH, Ferraresi C, Perez SE, Baldissera V, Parizotto NA. Effects of low-level laser therapy (808 nm) on isokinetic muscle performance of young women submitted to endurance training: a randomized controlled clinical trial. Lasers Med Sci. 2012 Mar;27(2):497-504. doi: 10.1007/s10103-011-0984-0. Epub 2011 Aug 26.
citation: Ferraresi C, de Brito Oliveira T, de Oliveira Zafalon L, de Menezes Reiff RB, Baldissera V, de Andrade Perez SE, Matheucci Junior E, Parizotto NA. Effects of low level laser therapy (808 nm) on physical strength training in humans. Lasers Med Sci. 2011 May;26(3):349-58. doi: 10.1007/s10103-010-0855-0. Epub 2010 Nov 18.
Clinical trial NCT01958216: in Vivo TICE (TransIntestinal Cholesterol Excretion)
Official title: In Vivo TICE (TransIntestinal Cholesterol Excretion) Measurement in Bile Duct Diverted Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Occlusion of Bile Duct With an External Bile Diversion.
Keywords: TICE-human-stable isotopes
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2013-10-09
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: So far, the liver has been the main target for cholesterol elimination. However, several recent studies performed in mice have described a new route of cholesterol excretion, the Trans-Intestinal Cholesterol Excretion or TICE. TICE allows direct elimination of plasma cholesterol in the feces directly via the intestine. Until now, only indirect evidence suggests that TICE is also active in humans, the goal of this proof of concept study is to provide the first proof of its existence in humans by using stable isotopes in patients with bile duct diversion.


Eligibility criteria: Inclusion Criteria:

- External bile duct diverted patients

Exclusion Criteria:

* Inflammatory bowel disease
* Aphagia
* Renal or hepatocellular insufficiency
* Primary intestinal tumor
* Cholangitis or severe sepsis
* Acute or chronic diarrhea

Primary outcomes:
measure: Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
timeFrame: Day 3
Secondary outcomes:
Other outcomes:
Locations:
city: Nantes
country: France
facility: University Hospital
Study officials:
affiliation: Nantes University Hospital
name: Bertrand Cariou, Pofessor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Moreau F, Blanchard C, Perret C, Flet L, Douane F, Frampas E, Mirallie E, Croyal M, Aguesse A, Krempf M, Prieur X, Pichelin M, Cariou B, Le May C. In vivo evidence for transintestinal cholesterol efflux in patients with complete common bile duct obstruction. J Clin Lipidol. 2019 Jan-Feb;13(1):213-217.e1. doi: 10.1016/j.jacl.2018.09.010. Epub 2018 Sep 21.
Clinical trial NCT04948216: Management and Healthcare Utilization of Patients With Chronic Airway Disease During the COVID-19 Epidemic
Official title: Management and Healthcare Utilization of Patients With COPD and Asthma During the COVID-19 Epidemic in Beijing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Disease, Chronic Obstructive
Asthma
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-01
Enrollment: 153
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients in the database were involved.

Brief summary: During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the influencing factors during the COVID-19 epidemic.

Detailed description: During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the relevant factors during the COVID-19 epidemic. Using cross-sectional research methods, telephone interviews and questionnaire surveys were used to investigate the management and healthcare utilization of patients with chronic airway disease （COPD and asthma）during the COVID-19 epidemic.

Eligibility criteria: Inclusion Criteria:

* COPD patients and asthma patients in the Chronic Airway Disease Database in Peking University Third Hospital.

Exclusion Criteria:

* Refusal to participate in this study; cognitive dysfunction.

Primary outcomes:
measure: Respiratory symptoms
timeFrame: through study completion, an average of 2 week.
measure: Frequency of exacerbation during the COVID-19 epidemic
timeFrame: through study completion, an average of 2 week.
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Yongchang Sun, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005116: Depression In Juvenile Diabetics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Diabetes Mellitus, Insulin-Dependent
Keywords: depression
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2000-04-14
Sex: ALL
Minimum age (years): 8
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Primary purpose: DIAGNOSTIC

Brief summary: Depression is one of the most common emotional problems among youths with insulin dependent diabetes mellitus (IDDM). It has been shown that depression in youths with IDDM lasts a while and may have a role in later complications of the medical condition. And yet, there are no psychological interventions appropriate for such youngsters. The purpose of this study is to modify a treatment called ''Contextual Psychotherapy'' (that has been developed for depressed youngsters) in order to address special needs of depressed youths with IDDM, and to ''pilot test'' the treatment. The youngsters to be recruited are those being cared for at the Diabetes Clinic of the Children's Hospital of Pittsburgh. The treatment includes a 3- month phase (16 sessions), followed by a 3-month ''booster'' phase (3 sessions), and two later follow-up evaluations.


Eligibility criteria: Inclusion Criteria:

* IDDM duration of less than 10 years
* No major medical disorder other than IDDM
* No psychotropic medications
* Meets psychiatric diagnostic criteria for depression
* Parent and child willing to participate

Exclusion Criteria:

* Does not live withing commuting distance
* Mental retardation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: WPIC
state: Pennsylvania
Study officials:
affiliation: U. Of Pittsburgh School of Medicine
name: Dr. Maria Kovacs
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00250016: Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
Official title: 1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Corpus Uteri
Endometrial Cancer
Keywords: Endometrium
Tissue
L9NC
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2005-11-07
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients participating in the trial - "Phase II Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients with Metastatic or Recurrent Cancer of the Endometrium"

Brief summary: The purpose of this study is to determine the amount of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in a patients blood and tumor.

Detailed description: Patients on this study are being asked to allow the researchers to take a piece of some normal endometrial tissue and tumor tissue. No additional endometrial tissue will be taken for this study other than what is surgically indicated to resect the patients tumor completely. Prior to this surgery, patients will receive one more dose of L9NC in the outpatient clinic in the same manner as the other L9NC treatments they have received. After the tumor has been removed, the tissue will be examined by a pathologist, who will take what is needed to diagnose the residual disease. What is not needed for patient care will be used for research. A piece of the tumor and some normal endometrial tissue surrounding the tumor will be sent to the Investigational Drug Program laboratory, which is located in the Cancer Center, to measure the amount of drug that is left in the patients tumor. The patients tissue will be kept until all tissues are collected from all patients, which could take up to 10 years. The tissue will not be used for any other purpose. The samples will be labeled with the patients initials.

Eligibility criteria: Inclusion Criteria:

* Patients participating in Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients with Metastatic or Recurrent Cancer of the Endometrium are eligible.

Exclusion Criteria:

* Not specified.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Claire F Verschraegen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00178516: Vitamin E and Male Infertility
Official title: Vitamin E and Male Infertility
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Male Infertility
Keywords: male
infertility
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: Mae Stone Goode Foundation
First posted: 2005-09-15
Enrollment: 58
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infertility clinic, community sample

Brief summary: The goal of this study is to determine whether there is a correlation between the levels of Vitamin E in sperm and sperm DNA fragmentation.

Previous research has shown that damage to the DNA in sperm may cause infertility or increase the chances of miscarriage, if the damage is extensive (eg. present in the overwhelming majority of sperm). Some studies suggest that DNA damage can be caused by oxidative stress. Antioxidants, such as Vitamin E, which are present in some foods, can prevent damage to cells from "free radicals", which are naturally present by-products of metabolism. We ask whether there is a correlation between sperm DNA damage and Vitamin E

Detailed description: Sperm DNA damage is an emerging cause of male infertility that is likely to be more common among men with increased reactive oxygen species in the ejaculate. Vitamin E can protect the sperm membrane from oxidative damage and increased levels are associated with low levels of reactive oxygen species. This is a study of Vitamin E levels in the spermatozoa and sera of 48 infertile men, and 20 fertile men as a control group, to look for correlations between sperm vitamin E levels and the degree of sperm DNA fragmentation. Dietary intake of antioxidants will also be included.

Eligibility criteria: Inclusion Criteria:

* infertile men with previously abnormal semen analyses.
* Control group: fertile adult males

Exclusion Criteria:

* Proxceed use within 3 months of the start of study.
* Vitamin E supplements with \> 45 IU daily

Primary outcomes:
measure: correlate vitamin E levels in spermatozoa with degree of DNA fragmentation in infertile men
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center, Department of OB/GYN
state: New York
Study officials:
affiliation: University of Rochester
name: Vivian Lewis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01745016: Effect of Beta-Alanine on Heart Rate Response
Official title: The Effect of 28 Days of Beta-alanine Supplementation on the Physical Working Capacity at Heart Rate Threshold (PWCHRT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise
Fatigue
Keywords: dietary supplement
carnosine
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
First posted: 2012-12-07
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL

Brief summary: Beta-alanine, as a method to increase muscle carnosine, has been shown to enhance muscle buffering capacity and delay fatigue. Various fatigue tests have been utilized to examine the effectiveness of beta-alanine supplementation. The physical working capacity test has been used to show significant increases in physical working capacities following supplementation. The physical working capacity tests were originally developed by Moritani et al. 1981 and Devries et al. 1982 to measure the point of onset of muscular fatigue. It is hypothesized that beta-alanine will increase physical working capacity at heart rate threshold, thereby signifying a delay in fatigue.

Detailed description: An equal number of men and women will be recruited \[Men, n=20 (10 placebo \[PL\]; 10 beta-alanine (Active)\]; \[Women,n=20 (10 PL; 10 Active)\]. Men and women will be randomly assigned to respective groups to allow for equal numbers in supplement and placebo groups.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 18-35 years old
* Be recreationally active (defined as accumulating 1-5 hours of moderate intensity

Exclusion Criteria

* Any health risks or indicators that would prevent them from participating in physical activity, as determined by a health history questionnaire
* Must not have taken performance enhancing supplements containing beta-alanine or creatine during the last 3 months

Primary outcomes:
measure: Physical working capacity at heart rate threshold
timeFrame: 0 to 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: UNC Exercise and Sport Science
state: North Carolina
Study officials:
References:
Clinical trial NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Alcohol Use Disorder
Keywords: Alcohol consumption
Moderate to severe alcohol use disorder
Lead sponsor: Imbrium Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: Purdue Pharma LP
First posted: 2024-08-09
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.


Eligibility criteria: Key Inclusion Criteria include:

* Male and female age ≥18 years.
* Diagnosis of moderate or severe alcohol use disorder.
* Currently seeking treatment for alcohol use disorder.
* Has 4 or more heavy drinking days (HDD) in each of the 4 weeks prior to baseline visit.

Key Exclusion Criteria include:

* Subjects that meet current DSM-5 criteria for moderate or severe substance use disorder other than alcohol and nicotine.

Other protocol-specific inclusion and exclusion criteria may apply.

Primary outcomes:
measure: Percent heavy drinking days (HDD)
timeFrame: Day 57
Secondary outcomes:
measure: Number of standard unit drinks
timeFrame: Day 57
measure: Percent of drinking days (PDD)
timeFrame: Day 57
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Belmont Medical Office
state: New York
city: Baytown
country: United States
facility: Inquest Clinical Research
state: Texas
city: Houston
country: United States
facility: Cebis Usa, Llc
state: Texas
city: Bucharest
country: Romania
facility: Bio Terra Med SRL
city: Bucharest
country: Romania
facility: Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila"
city: Bucharest
country: Romania
facility: Cabinet Medical Individual Dr. Andreea Popa
Study officials:
References: